ADMA Biologics (NASDAQ:ADMA) Issues Earnings Results, Beats Expectations By $0.03 EPS

ADMA Biologics (NASDAQ:ADMA - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.03, Briefing.com reports. The business had revenue of $81.90 million during the quarter, compared to the consensus estimate of $77.28 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The business's quarterly revenue was up 43.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.03) EPS. ADMA Biologics updated its FY 2024 guidance to EPS and its FY 2025 guidance to EPS.

ADMA Biologics Trading Up 27.1 %

Shares of NASDAQ ADMA traded up $1.88 during mid-day trading on Friday, hitting $8.81. 11,697,433 shares of the company traded hands, compared to its average volume of 2,689,451. The business has a 50 day moving average of $6.33 and a two-hundred day moving average of $5.09. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -69.31 and a beta of 0.43. ADMA Biologics has a 1 year low of $3.06 and a 1 year high of $9.02. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04.

Insiders Place Their Bets

In other news, Director Steve Elms sold 407,000 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total value of $2,527,470.00. Following the completion of the sale, the director now directly owns 3,208,671 shares of the company's stock, valued at $19,925,846.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 639,895 shares of company stock worth $3,927,169. Company insiders own 3.70% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ADMA. HC Wainwright raised their target price on shares of ADMA Biologics from $7.50 to $10.00 and gave the stock a "buy" rating in a report on Friday. Mizuho lifted their target price on ADMA Biologics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Friday. Raymond James increased their price target on ADMA Biologics from $8.00 to $10.00 and gave the stock a "strong-buy" rating in a research note on Friday. Finally, Cantor Fitzgerald raised their target price on shares of ADMA Biologics from $8.00 to $10.00 and gave the company an "overweight" rating in a research note on Friday. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ADMA Biologics presently has an average rating of "Buy" and an average price target of $10.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.